

1 **Systematic review and meta-analysis of protocols and yield of** 2 **direct from sputum sequencing of *Mycobacterium tuberculosis***

3
4 B.C. Mann^{1,3}, J. Loubser¹, S. Omar¹, C. Glanz¹, Y. Ektefaie³, K.R. Jacobson², R.M.
5 Warren^{1*}, M.R. Farhat^{3*}

6
7 1. DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, SAMRC Centre for Tuberculosis Research,
8 Division of Molecular Biology and Human Genetics, Depts of Biomedical Sciences, Faculty of Medicine and Health
9 Sciences, Stellenbosch University, Cape Town, South Africa

10 2. Section of Infectious Diseases, Boston University School of Medicine, Boston, MA, USA

11 3. Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA

12 *Co-senior authors
13
14

15 Abstract

16
17 Direct sputum whole genome sequencing (dsWGS) can revolutionize *Mycobacterium*
18 *tuberculosis* (*Mtb*) diagnosis by enabling rapid detection of drug resistance and strain diversity
19 without the biohazard of culture. We searched PubMed, Web of Science and Google scholar,
20 and identified 8 studies that met inclusion criteria for testing protocols for dsWGS. Utilising
21 meta-regression we identify several key factors positively associated with dsWGS success,
22 including higher *Mtb* bacillary load, mechanical disruption, and enzymatic/chemical lysis.
23 Specifically, smear grades of 3+ (OR = 14.7, 95% CI: 3.5, 62.1; p = 0.0005) were strongly
24 associated with improved outcomes, whereas decontamination with sodium hydroxide
25 (NaOH) was negatively associated (OR = 0.005, 95% CI: 0.001, 0.03; p = 7e-06), likely due
26 to its harsh effects on *Mtb* cells. Furthermore, mechanical lysis (OR = 193.3, 95% CI: 11.7,
27 3197.8; p = 0.008) and enzymatic/chemical lysis (OR = 18.5, 95% CI: 1.9, 183.1; p = 0.02)
28 were also strongly associated with improved dsWGS. Across the studies, we observed a high
29 degree of variability in approaches to sputum pre-processing prior to dsWGS highlighting the
30 need for standardized best practices. In particular we conclude that optimizing pre-processing
31 steps including decontamination with the exploration of alternatives to NaOH to better
32 preserve *Mtb* cells and DNA, and best practices for cell lysis during DNA extraction as
33 priorities. Further and considering the strong association between *Mtb* load and successful
34 dsWGS, protocol improvements for optimal sputum sample collection, handling, and storage
35 could also further enhance the success rate of dsWGS.

36
37

38 Introduction

39

40 Tuberculosis (TB) caused by the bacillus *Mycobacterium tuberculosis* (*Mtb*) remains the most
41 common cause of death from any single infectious pathogen (1, 2). Progress in eradicating
42 TB is hampered by the emergence of multidrug-resistant (MDR) and extensively drug resistant
43 (XDR) *Mtb* strains. According to the latest WHO Global Tuberculosis Report approximately
44 half a million people worldwide developed rifampicin-resistant TB (RR-TB), 78% of which had
45 MDR-TB, defined as resistant to at least isoniazid (INH) and rifampicin (RIF) (2). Next
46 Generation Sequencing (NGS) advances over the past decade have provided the ability to
47 rapidly sequence the whole *Mycobacterium tuberculosis* genome; supplying an extraordinary
48 tool to study the genetic epidemiology of this pathogen, while also detecting single nucleotide
49 polymorphisms (SNPs) and other mutations which can be used to predict susceptibility to first-
50 line drugs (3, 4). Several rapid genotypic drug susceptibility testing (DST) methods are
51 currently endorsed by the WHO, but most of these tests do not provide a comprehensive
52 summary of a patient's drug resistance (DR) profile, since most of these assays only focus on
53 a limited number of targets involved with DR (5). Recently the introduction of targeted NGS
54 (tNGS) has expanded the number of drugs and targets assayed substantially (6). Whole
55 genome sequencing (WGS) however can assay the full breadth of genetic variation and is
56 most comprehensive for predicting phenotype from genotype for *Mtb* (7, 8).

57

58 *Mtb* sequencing is still hindered by the long and cumbersome process of culturing *Mtb* for DNA
59 extraction. This process can take weeks and sometimes even months (4). In addition to the
60 long culture period, the culture-based approach has an additional limitation, as culture can
61 change the population structure of the original sample due to the selection of subpopulations
62 more suited to growth in culture and random genetic drift (9). The logical step to avoid these
63 limitations is to sequence *Mtb* directly from clinical specimens. To date several studies have
64 demonstrated that sequencing from direct patient specimens is possible with varying levels of
65 success (3, 4, 9–12). Commercial tNGS assays include a targeted polymerase chain reaction
66 (PCR) amplification step that helps improve sequencing coverage from direct samples,
67 however even tNGS performs poorly on sputum with lower bacillary burden (including Xpert
68 medium and low, or smear negative sputum) with 50-78% or more of test samples yielding
69 only partial coverage of the targets (6, 8, 13). For direct whole genome sequencing, most
70 studies have relied on the use of target capture and enrichment technology which enriches
71 target DNA with a set of target-specific bait probes during library preparation. Others have
72 opted for a selective lysis approach, attempting to selectively lyse contaminating host and

73 bacterial cells, followed by the depletion of contaminating DNA by enzymes such as DNase,
74 either forgoing or only turning to target enrichment in samples for which it was deemed
75 necessary by additional quality control (QC) steps (3, 4, 10, 11). This systematic review and
76 meta-analysis aims to summarize DNA target and non-target-based methods previously
77 utilized to perform whole genome sequencing *Mtb* from direct patient samples. We classify
78 the different approaches used in the literature and perform an individual sample meta-analysis
79 of the effect of specific sample processing steps on direct sequencing success. Although
80 focused on WGS, reviewing non-target-based methods can also have implications for
81 improving yield of tNGS from direct patient samples.

82

83 Methods

84

85 Search strategy

86

87 In brief we searched PubMed and Web of Science, looking for English articles published on
88 *Mtb* direct sputum whole genome sequencing (dsWGS) to compare various approaches that
89 have previously been applied for successful dsWGS of *Mtb*. This was done to highlight gaps
90 in the current applied methodology that can be improved upon to better facilitate dsWGS. The
91 literature search was carried out using the following keywords “direct + sputum + sequencing
92 + tuberculosis + mycobacteria” and was conducted by three independent reviewers. The three
93 reviewers reviewed titles, abstract, key words and subsequently the full texts to identify and
94 include articles meeting the study inclusion and not meeting the exclusion criteria below.

95 An ethical review was deemed unnecessary as this was a secondary analysis of published
96 articles. We conducted an additional search of Google scholar to identify any relevant articles
97 not identified in the original search. No grey literature, conference papers or unpublished
98 works were included in this analysis because of uncertainty over the relevance and validity of
99 the presented data.

100

101

102

103

104 Inclusion and exclusion criteria

105

106 The inclusion criteria for eligible publications were defined as all articles that:

- 107 • Studied *Mtb*.
- 108 • Attempted direct whole genome sequencing or target capture/target enrichment
109 followed by whole genome sequencing (i.e. no targeted PCR) directly on sample
110 without intervening culture.
- 111 • Reported on *Mtb* input sputum smear grade or Xpert CT or other *MTB* input DNA
112 quantification.
- 113 • Reported on one or more of the following outputs:
 - 114 ○ *Mtb* genomic coverage of drug resistance genes (any subset) or the whole
115 genome.
 - 116 ○ Resistance mutation recall relative to phenotype or to sequencing after culture.
 - 117 ○ Lineage mutation recall relative to sequencing after culture.
- 118 • Provided methodological detail on the sputum processing protocol.

119

120 The exclusion criteria included articles that:

- 121 • Focused on the application to pathogens other than *Mtb*.
- 122 • Focused on samples other than sputum.

123

124 Data extraction

125

126 Three reviewers independently extracted data from the included studies. The following
127 background information was extracted from eligible papers: Author details, year of publication
128 and population. Sixteen technical variables were extracted under three categories including
129 Sample data and characteristics, Methodology and Results (Table 1). Data extracted were
130 compiled into several predesigned spreadsheets. In instances where data was represented
131 graphically, the authors were contacted to provide the original numerical data used to generate
132 the graphs. If the authors could not be reached or the information was no longer available, we
133 extracted the numerical values from the graphical representations using available software
134 (PlotDigitizer).

135

136 **Table 1 Summary of data items extracted from articles fulfilling**
137 **inclusion and exclusion criteria**

Data group	Number	Data extracted
Sample data and characteristics	1	Population group
	2	Sample number
	3	Sample types
	4	Sputum culture pairs
	5	Xpert or qPCR data (quantitative or semiquantitative)
	6	Smear data
Methodology	7	Sample pre-treatment and enrichment methodology
	8	DNA extraction methodology
	9	DNA concentrations
	10	Bioinformatics methodology
Results	11	Coverage for both culture and direct sputum samples
	12	Percentage on target reads for direct sputum samples

138

139 [Bioinformatics analysis](#)

140

141 Sequencing data was downloaded for each included study, either from NCBI GenBank or
142 the European Nucleotide Archive (ENA). Initial quality assessment was done using fastQC,
143 version 0.11.9, followed by adapter removal, quality filtering and per-read low quality base
144 trimming using fastP, version 0.20.1 (14). Following quality control, reads were taxonomically
145 classified using the metagenomic classification tool Kraken2 using the standard database
146 (version 2.0.8) (Wood *et al.*, 2019). Mycobacterial reads were extracted and aligned using
147 bwa-mem2 (version 2.2.1) to the H37Rv reference genome AL123456 (15). Duplicates were
148 removed using Picard and excluded in downstream analyses. Alignment statistics, including
149 number of reads, depth and breadth of coverage and GC-content were determined and
150 visualised using Qualimap (version 2.2.2c) (16).

151

152 [Statistical analysis](#)

153

154 To assess the effects of various factors on genome and DR region coverage (DR regions
155 comprised of 73 genomic regions strongly associated with a DR phenotype, identified and
156 curated by the well-known TB-Profiler tool) (17), we employed regression comparing
157 generalized linear mixed models (GLMMs) to support batch control across studies, and a

158 generalized linear model (GLM) without batch control. We found no significant batch effects
159 across the studies and report the GLM results in the main text and the GLMM results in the
160 supplement (Supplementary Tables Y and Z). We assessed the fixed effects of several factors
161 including: smear grade, mechanical disruption, enzymatic/chemical lysis, decontamination,
162 and heat treatment on whole genome coverage (>5x at >90%) and coverage of DR conferring
163 regions (>5x at >95%). Given the limited number of samples sequenced directly we limited
164 the analysis to samples that underwent target capture and enrichment and excluded directly
165 sequenced samples. Associations were assessed using the Wald test with significance
166 assessed at a P-value <0.05. Two processing steps homogenisation and contamination
167 depletion were coded but excluded from the final model due to their utilization in all but one
168 study, or only two target capture studies respectively making it difficult to evaluate their effect.

169

170 Results


171

172 Search strategy and study selection

173

174 We identified 134 and 91 studies respectively from the PubMed and Web of Science searches.
175 One additional record was identified using a Google scholar search. Three independent
176 reviewers read titles, abstracts, and keywords to assess for duplicates and adherence to
177 inclusion and exclusion criteria. Records that were not excluded at this stage were reviewed
178 in full text to assess the same; 219 records were excluded leaving a total of 8 studies for
179 inclusion in this review.

180



181

182

Figure 1: Flow diagram outlining study selection. Abbreviation: PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

183

184

185

186

187 Characteristics of included studies

188

189 The number of participants per study ranged from 34 to 100; 5 studies sequenced directly
190 from sputum and compared with sequencing after culture. The largest number of sputum/
191 culture pairs available from a single study was 43. All studies except 1 included smear data
192 as a semi quantitative measure of bacilli load, and 3 studies included Xpert cycle threshold
193 (Ct) values. Only 2 studies quantified DNA in the input sample by means of qPCR, an
194 additional 2 studies report that qPCR was done to assess bacillary load, but results were not
195 reported, or accessible after contacting the authors (Supplementary Table 1).


196

197 Current approaches facilitating direct sputum sequencing from clinical specimens

198

199 The selected studies spanned three primary avenues to facilitate dsWGS with various ways
200 of pre-treating samples before proceeding to one or the other (Figure 2). We define these

201 methods broadly as: 1) non- (DNA) target methods: including selective lysis or other physical
202 or chemical enrichment, which involves the enrichment of *Mtb* cells by breaking down
203 contaminating host and/or commensal bacterial cells, followed by depletion of contaminating
204 DNA by washing or enzymatic degradation and then sequencing; 2) DNA targeting methods
205 specifically the bait capture approach that capture and enrich for *Mtb* DNA with specific
206 DNA/RNA bait probes and; 3) a combination approach involving both selective lysis and
207 contaminating DNA depletion, while also employing bait capture probes (3, 4, 9–12, 18).



the pre-treatment steps. This includes 1) the selective lysis approach for further *Mtb* enrichment where non *Mtb* cells and their DNA are depleted by chemical and/or enzymatic means, or 2) the target capture and enrichment approach where target specific DNA is enriched by means of DNA/RNA bait probes. Studies numbered in the figure as they appear in the bibliography. Created in <https://BioRender.com>

229

230

231

232 [Key pre-processing steps that may contribute to the success of dsWGS](#)

233

234 We aimed to identify key steps that may contribute to the enrichment of the *Mtb* target and
 235 thus success of dsWGS (Table 2). A step was marked with X if it formed part of the workflow
 236 described in the paper. We identified seven steps within either a targeted or non-targeted
 237 approach that were employed across the eight studies: specifically, sputum homogenisation,
 238 sputum decontamination, heat inactivation, host DNA depletion, commensal microbe DNA
 239 depletion, DNA extraction and target enrichment. We briefly summarize the approaches taken
 240 under each step below. A more detailed summary of the methodology applied at each step
 241 can be found in Supplementary Table 2.

242

243 **Table 2. Direct sputum processing workflow as outlined for each individual**
 244 **study**

Study (reference)	Homogenisation	Decontamination	Heat inactivation	Host DNA depletion	Depletion of commensal microflora	DNA extraction			DNA/RNA bait capture
						Mechanical	Enzymatic	Chemical	
Brown <i>et al.</i> 2015 (3)	X	X	X			X			X
Votintseva <i>et al.</i> 2017 (10)	X	X	X	X		X			
Doyle <i>et al.</i> 2018 (11)						X	X	X	X
Nimmo <i>et al.</i> 2019 (9)	X		X				X	X	X
Soundararajan <i>et al.</i> 2020 (12)	X			X		X	X	X	X
Goig <i>et al.</i> 2020 (4)	X	X	X	X	X	X			X
George <i>et al.</i> 2020 (18)	X		X			X			
Macedo <i>et al.</i> 2023 (21)	X	X	X				X	X	X

245

246 [Sputum homogenisation and decontamination](#)

247

248 Although none of the studies utilised homogenisation or decontamination with the aim of
 249 enriching for the *Mtb* target, these steps were still incorporated as part of sample pre-
 250 processing prior to DNA extraction. All studies reviewed, except one, included a
 251 homogenisation step, but approaches varied from the use of the mucolytic agent N-acetyl-L-
 252 cysteine (NALC) to the reducing agent dithiothreitol (DTT) or other DTT containing products

253 such as Sputasol. After homogenisation sputum samples are decontaminated in four studies
254 using sodium hydroxide (NaOH) with the goal of preferentially killing other bacteria, fungi, and
255 viruses, thereby reducing the risk of these contaminants influencing diagnostic testing
256 (Supplementary Table 3).

257 Heat inactivation

258

259 All the studies reviewed except two applied a heat inactivation step commonly used to reduce
260 the biohazard involved with downstream processing (Table 2 and 3). Heat inactivation of *Mtb*
261 specimens involved exposing samples to high temperatures ranging between 80 and 95°C for
262 times ranging from 15 min to 1 hour defined period (3, 4, 9, 11, 12, 18, 21). One of the studies
263 (George *et al.* 2020) demonstrated that heat inactivation can achieve enrichment of tough to
264 lyse cells such *Mtb* but required the addition of a specialised thermal protection buffer to
265 maintain the integrity of *Mtb* DNA during extensive heating (30 min at 99°C) which also
266 subsequently lead to the degradation of any extracellular host DNA (18).

267

268 Host and commensal microbe DNA depletion

269

270 Votinseva *et al.* (2017) and Soundararajan *et al.* (2020), aimed to enrich for *Mtb* by applying
271 commercially available kits namely the MolYsis Basic5 kit and the Ultra Deep Microprep DNA
272 isolation kit (Molzym, Germany) for the depletion of host DNA prior to *Mtb* WGS. Goig *et al.*
273 (2020), used GTC solution (4M guanidinium thiocyanate 4M, 0.5% w/v sodium N-lauryl
274 sarcosine, 25mM trisodium citrate, 0.1M 2mercaptoethanol, 0.5% w/v Tween 80) instead to
275 lyse eukaryotic cells in conjunction with DNase. In addition to this, the study by Galo *et al.*
276 (2020), was also the only study to directly perform additional depletion with the aim to not only
277 lyse eukaryotic cells but also gram-negative bacterial cells utilising a GTC buffer, while leaving
278 tough-walled *Mtb* cells intact (4).

279

280 Lysis and DNA extraction

281


282 Mycobacteria are known to be difficult to lyse (22). Failure to achieve adequate lysis in the
283 context of dsWGS can result in a biased representation of target *Mtb* DNA relative to
284 contaminating DNA (10, 22). DNA concentrations post extraction were available for four of the
285 studies included in this review (Figure 3). DNA extraction methods varied across the reviewed
286 studies (Supplementary Table 3). All studies, except Soundararajan *et al.* (2020) and Macedo
287 *et al.* (2023), employed a combination of chemical and mechanical cell lysis. Soundararajan *et*

288 *al.*, extracted DNA utilising the Ultra Deep Microprep DNA isolation kit (Molzym, Bremen,
 289 Germany), while Macedo *et al.* utilised the QIAmp DNA Mini Kit, both of which according to
 290 the manufacturer's instructions include both chemical and enzymatic means to facilitate lysis
 291 but omit any mechanical steps. None of the studies assessed the effect of specific pre-
 292 processing/DNA extraction steps on total DNA concentration by molecular quantification of
 293 DNA before and after any given step.

294

295

296



Study (Reference)	Average DNA yield ng/ul	Processing steps that may impact DNA yield
Goig <i>et al</i> 2020 (4)	0.57±0.86	Heat inactivation, decontamination, selective lyses with GTC, DNase treatment
Sundaresan <i>et al.</i> 2020 (12)	39.42±34.93	Ultra-Deep Microprep DNA isolation kit
Nimmo <i>et al.</i> 2019 (9)	0.97±0.97	Heat inactivation, decontamination
Votintseva <i>et al.</i> 2017 (10)	6.18±3.1	Heat inactivation, decontamination, treatment with Molzym Basic5

297

298

299 Figure 3: DNA concentration measured after DNA extraction and prior to target capture (if any) for the 4 studies
 300 with available data.

301

302 Target enrichment

303

304 Six studies used DNA or RNA bait capture to enrich for *Mtb* DNA (3, 4, 9–12, 18, 21).
 305 However, only two studies (Brown *et al.* (2015) and Goig *et al.* (2020)), compared sequencing
 306 yield with or without bait capture to measure the increase of sequencing reads attributed to
 307 the *Mtb* target . The former compared the percentages of on-target reads (%OTR), and the
 308 mean sequencing depths for two sputum samples. Brown *et al.* reported a percent of on-target
 309 reads (%OTR) of 0.3%, with a sequencing depth of 4.6x without bait capture, compared to
 310 82% and 200x respectively with bait capture. Goig *et al.*, quantified the target *Mtb* DNA in the
 311 input and used this information to target bait enrichment to the lowest input samples. We used
 312 the raw data provided with this publication to assess percentage of *Mtb* target pre and post

313 bait capture (Figure 4). The average % of *Mtb* target pre-bait capture was 1,67% compared to
314 48,5% post-capture (4).

315

316

Goig et al. With - without bait capture

317

318


319

320

321

322

323



324

325

Figure 4 Increase in *Mtb* target read % in samples sequenced with and without bait capture from Goig *et al.*, 2020 (4). Note the y-axis is on the logarithmic scale.

326

327 Processing steps predictive of successful dsWGS

328

329 The effects of sample characteristic (smear grade), and processing steps prior to target
330 enrichment and sequencing (mechanical disruption for lysis, enzymatic/chemical lysis,
331 decontamination with NaOH and heat treatment) were studied as predictors dsWGS success
332 using logistic regression (Methods) with data extracted for 289 samples. The effect of
333 processing steps was consistent across the dsWGS success metric used (>95% of drug
334 resistance regions covered at >5x read depth or >90% of the whole genome covered at >5x
335 depth, Table 3, Supplementary Table Y) and we observed no evidence of batch effects by
336 study (Supplementary table Z). The results identify samples with higher smear grade as more
337 likely to be successfully sequenced directly, as expected. In addition, mechanical disruption,
338 and enzymatic/chemical lysis were also associated with higher dsWGS success prior to target
339 capture. Sputum decontamination with NaOH on the other hand resulted in lower dsWGS
340 success when used prior to target capture (Table 3).

341

Table 3 Sputum processing step that are significantly associated with dsWGS success based on the whole genome coverage generalized linear model.

Characteristic	OR	95% CI	p-value
Smear neg	ref		
2+,1+,scanty	3.4	(0.98, 12.1)	0.07
3+	14.7	(3.5, 62.1)	0.0005
Mechanical lysis	193.3	(11.7, 3197.8)	0.008
Enzymatic/Chemical lysis	18.5	(1.9, 183.1)	0.02
Decontamination	0.005	(0.001, 0.03)	7e-06
Heat Inactivation	2.25	(1.1, 4.5)	0.02

Associations were performed using a sample-level logistic regression model pooled across studies with dsWGS success defined as whole genome coverage >90% at read depth of >5x per site. OR = Odds Ratio, CI = Confidence Interval.

342

343 Discussion

344

345 This systematic review and meta-analysis summarize key experimental steps that may
346 influence the success of dsWGS for *Mtb*. We identified and reviewed 226 study records,
347 ultimately including 8 studies that met our inclusion criteria. Included studies varied in sample
348 size, ranging from 34 to 100 participants/*Mtb* isolates, and utilized various approaches for the
349 pre-process of sputum samples prior to sequencing. The current review demonstrates that
350 although there is overlap in the applied methodology across studies there is simultaneously a
351 lot of variability in the specific processing steps employed for sequencing directly from sputum.
352 This review classifies key pre-processing steps that may or may not contribute to the success
353 of dsWGS, these include sputum homogenization, decontamination, heat inactivation,
354 depletion of host and commensal microbial DNA, lysis and DNA extraction, and target
355 enrichment through DNA/RNA bait capture (3, 9, 11, 12, 21).

356

357 Due to the amount of contaminating cells and DNA present in sputum the main overlapping
358 trend across studies is the utilisation of bait capture and enrichment probes which was utilised
359 by all the reviewed studies except that of Votintseva *et al.* (2017). Bait capture relies on the
360 hybridisation of *Mtb* specific biotinylated DNA/RNA probes that bind to complimentary *Mtb*
361 DNA, bait/target DNA hybrids are then captured with streptavidin magnetic beads and pulled
362 down magnetically allowing for the selective enrichment of the *Mtb* target (23). Studies by
363 Brown *et al.* (2015) and Goig *et al.* (2020), have sequenced samples both enriched and

364 unenriched for comparison clearly demonstrating the effectiveness of the addition of target
365 capture and enrichment systems for dsWGS, however the impact of additional pretreatment
366 steps has not yet been elucidated (3, 4). Homogenization, heat inactivation, and the depletion
367 of contaminating host and bacterial cells/DNA are key steps identified during the literature
368 review that could potentially enhance *Mtb* enrichment. Currently reviewed studies have not
369 critically assessed the impact of various sample treatment/preparation steps on the final
370 outcome/success of dsWGS, but have consistently highlighted correlation between smear
371 grade/*Mtb* load and improved sequencing performance (11, 12, 21).

372

373 Other than bait capture, there is limited data on the impact of specific sputum processing steps
374 on dsWGS success (3, 4, 9–12, 21). To address this, we used logistic regression to perform
375 a meta-analysis of the effect of a subset of these steps on dsWGS success controlling for the
376 *Mtb* load in the sputum as measured by smear microscopy. Study data allowed the evaluation
377 of the effects of four processing steps and only prior to target capture: specifically, sputum
378 decontamination with NaOH, mechanical disruption, enzymatic/chemical lysis, and heat
379 treatment. The results support the latter three steps as significantly increasing the success of
380 sputum dsWGS. The *Mtb* cell wall is difficult to lyse and this may explain why a combination
381 approach which involves chemical, enzymatic and mechanical lysis contributes to improved
382 *Mtb* DNA recovery and thus also potentially improved sequencing results (4, 24). Although
383 heat inactivation was employed with the goal of sterilizing the sample and thereby reduce the
384 biohazard risk of downstream processing, George *et al.* (2020) (18) demonstrated that heat
385 inactivation can enrich for tough-to-lyse cells like *Mtb* in the setting of thermal protection buffer
386 supporting the meta-analysis association between heat duration and temperature and dsWGS
387 success that we observe across studies. The available data limited our ability to study the
388 effect of other processing steps, such as host DNA depletion, using the MoYsis Basic5 kit,
389 the Ultra Deep Microprep DNA isolation kit, or a GTC solution combined with DNase treatment
390 (4, 10, 12). Confirming the effectiveness of these methods in depleting host DNA and enriching
391 *Mtb* will require additional future study.

392

393 Our meta-analysis supports sputum decontamination using NaOH treatment as decreasing
394 dsWGS success in the setting of target capture. The use of NaOH is standard practice to
395 reduce live contaminants in sputum prior to *Mtb* culture (19). While it is known to create a
396 highly alkaline environment that is inhospitable to most microorganisms except *Mtb*, its impact
397 on dsWGS, specifically in terms of *Mtb* enrichment and potential loss of target cells and DNA,
398 has not been thoroughly evaluated (25, 26). NaOH can selectively lyse contaminating cells

399 that are not of interest for downstream analysis, but studies support a risk of *Mtb* cell loss (4,
400 19, 25, 26). Our finding raises a need to reevaluate the effect of NaOH treatment on sample
401 composition and the exploration of alternative methods as potentially more suitable for WGS
402 which does not require viable *Mtb* bacilli.

403

404 Conclusion

405

406 Despite the observed heterogeneity of approaches for dsWGS, a common trend observed
407 during the course of this systematic review and meta-analysis is the utilization of target capture
408 and enrichment probes, which is observed to be highly effective in enhancing *Mtb* sequencing
409 from direct patient samples (3, 4, 9, 12). The efficacy of these probes nevertheless depends
410 on the overall *Mtb/Mtb* DNA load in sputum. Target capture probes are expensive and
411 alternative or additional processing steps that can deplete contaminants or directly enrich for
412 *Mtb* DNA will be beneficial to facilitate dsWGS and reduce cost (4, 10). Future research should
413 thus focus on refining the identified pre-processing steps to enhance the robustness and also
414 reliability of dsWGS with the ultimate aim of developing standardized pre-processing protocols
415 to advancing DR profiling directly from clinical sputum samples (4, 9, 10, 12). Considering the
416 importance of *Mtb* load highlighted in the current study a suggested additional research
417 direction is to optimise sputum collection, standardize sputum volume, storage, handling and
418 transport with the aim of further improving *Mtb* bacilli yield prior to the application of target
419 capture and enrichment (27, 28).

420

421 Acknowledgements

422

423 This work was supported by the National Institutes of Health (NIH - R01 AI155765). All claims
424 expressed in this article are solely those of the authors and do not represent those of their
425 affiliated organizations, or the funders. The funder had no role in study design, data, data
426 analysis, the decision to publish, or preparation of the manuscript.

427

428

429

430 References

431

- 432 1. Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba P, Kapata N, Mfinanga S,
433 Hasnain SE, Katoto PDMC, Bulabula ANH, Sam-Agudu NA, Nachega JB, Tiberi S,
434 McHugh TD, Abubakar I, Zumla A. 2021. Global Tuberculosis Report 2020 –
435 Reflections on the Global TB burden, treatment and prevention efforts. *Int J Infect Dis*
436 113:S7–S12.
- 437 2. Global Tuberculosis Report 2024. [https://www.who.int/teams/global-tuberculosis-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024)
438 [programme/tb-reports/global-tuberculosis-report-2024](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024). Retrieved 13 November 2024.
- 439 3. Brown AC, Bryant JM, Einer-Jensen K, Holdstock J, Houniet DT, Chan JZM, Depledge
440 DP, Nikolayevskyy V, Broda A, Stone MJ, Christiansen MT, Williams R, McAndrew MB,
441 Tutill H, Brown J, Melzer M, Rosmarin C, McHugh TD, Shorten RJ, Drobniewski F,
442 Speight G, Breuer J. 2015. Rapid Whole-Genome Sequencing of Mycobacterium
443 tuberculosis Isolates Directly from Clinical Samples. *J Clin Microbiol* 53:2230–2237.
- 444 4. Goig GA, Cancino-Muñoz I, Torres-Puente M, Villamayor LM, Navarro D, Borrás R,
445 Comas I. 2020. Whole-genome sequencing of Mycobacterium tuberculosis directly
446 from clinical samples for high-resolution genomic epidemiology and drug resistance
447 surveillance: an observational study. *The Lancet Microbe* 1:e175–e183.
- 448 5. WHO consolidated guidelines on tuberculosis: Module 3: diagnosis – rapid diagnostics
449 for tuberculosis detection . 2021. WHO consolidated guidelines on tuberculosis: Module
450 3: diagnosis – rapid diagnostics for tuberculosis detection. World Health Organization,
451 Geneva. <http://www.ncbi.nlm.nih.gov/books/NBK572344/>. Retrieved 19 July 2023.
- 452 6. Mansoor H, Hirani N, Chavan V, Das M, Sharma J, Bharati M, Oswal V, Iyer A, Morales
453 M, Joshi A, Ferlazzo G, Isaakidis P, Ndlovu Z, England K. 2023. Clinical utility of target-

- 454 based next-generation sequencing for drug-resistant TB. *Int J Tuberc Lung Dis* 27:41–
455 48.
- 456 7. Ness TE, DiNardo A, Farhat MR. 2022. High Throughput Sequencing for Clinical
457 Tuberculosis: An Overview. *Pathogens* 11:1343.
- 458 8. Dookie N, Khan A, Padayatchi N, Naidoo K. 2022. Application of Next Generation
459 Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis:
460 Updates on Recent Developments in the Field. *Frontiers in Microbiology* 13.
- 461 9. Nimmo C, Shaw LP, Doyle R, Williams R, Brien K, Burgess C, Breuer J, Balloux F,
462 Pym AS. 2019. Whole genome sequencing *Mycobacterium tuberculosis* directly from
463 sputum identifies more genetic diversity than sequencing from culture. *BMC Genomics*
464 20:389.
- 465 10. Votintseva AA, Bradley P, Pankhurst L. 2017. Same-Day Diagnostic and Surveillance
466 Data for Tuberculosis via Whole-Genome Sequencing of Direct Respiratory Samples.
467 *Journal of Clinical Microbiology* 55.
- 468 11. Doyle RM, Burgess C, Williams R, Gorton R, Booth H, Brown J, Bryant JM, Chan J,
469 Creer D, Holdstock J, Kunst H, Lozewicz S, Platt G, Romero EY, Speight G, Tiberi S,
470 Abubakar I, Lipman M, McHugh TD, Breuer J. 2018. Direct Whole-Genome
471 Sequencing of Sputum Accurately Identifies Drug-Resistant *Mycobacterium*
472 *tuberculosis* Faster than MGIT Culture Sequencing. *J Clin Microbiol* 56:e00666-18.
- 473 12. Soundararajan L, Kambli P, Priyadarshini S, Let B, Murugan S, Iravatham C, Tornheim
474 JA, Rodrigues C, Gupta R, Ramprasad VL. 2020. Whole genome enrichment approach
475 for rapid detection of *Mycobacterium tuberculosis* and drug resistance-associated
476 mutations from direct sputum sequencing. *Tuberculosis* 121:101915.

- 477 13. Colman RE, Seifert M, Rossa AD Ia, Georghiou SB, Hoogland C, Uplekar S, Laurent S,
478 Rodrigues C, Kambli P, Tukvadze N, Maghradze N, Omar SV, Joseph L, Suresh A,
479 Rodwell TC. 2024. Evaluating culture-free targeted next-generation sequencing for
480 diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end
481 commercial workflows. *The Lancet Infectious Diseases* 0.
- 482 14. Chen S, Zhou Y, Chen Y, Gu J. 2018. fastp: an ultra-fast all-in-one FASTQ
483 preprocessor. *Bioinformatics* 34:i884–i890.
- 484 15. Vasimuddin Md, Misra S, Li H, Aluru S. 2019. Efficient Architecture-Aware Acceleration
485 of BWA-MEM for Multicore Systems, p. 314–324. *In* 2019 IEEE International Parallel
486 and Distributed Processing Symposium (IPDPS). IEEE, Rio de Janeiro, Brazil.
- 487 16. Okonechnikov K, Conesa A, García-Alcalde F. 2016. Qualimap 2: advanced multi-
488 sample quality control for high-throughput sequencing data. *Bioinformatics* 32:292–294.
- 489 17. Phelan JE, O’Sullivan DM, Machado D, Ramos J, Oppong YEA, Campino S, O’Grady
490 J, McNERNEY R, Hibberd ML, Viveiros M, Huggett JF, Clark TG. 2019. Integrating
491 informatics tools and portable sequencing technology for rapid detection of resistance
492 to anti-tuberculous drugs. *Genome Medicine* 11:41.
- 493 18. George S, Xu Y, Rodger G, Morgan M, Sanderson ND, Hoosdally SJ, Thulborn S,
494 Robinson E, Rathod P, Walker AS, Peto TEA, Crook DW, Dingle KE. 2020. DNA
495 Thermo-Protection Facilitates Whole-Genome Sequencing of Mycobacteria Direct from
496 Clinical Samples. *J Clin Microbiol* 58:e00670-20.
- 497 19. Dippenaar A, Ismail N, Grobbelaar M, Oostvogels S, de Vos M, Streicher EM, Heupink
498 TH, van Rie A, Warren RM. 2022. Optimizing liquefaction and decontamination of
499 sputum for DNA extraction from *Mycobacterium tuberculosis*. *Tuberculosis*
500 132:102159.

- 501 20. Burdz TVN, Wolfe J, Kabani A. 2003. Evaluation of sputum decontamination methods
502 for *Mycobacterium tuberculosis* using viable colony counts and flow cytometry.
503 *Diagnostic Microbiology and Infectious Disease* 47:503–509.
- 504 21. Macedo R, Isidro J, Ferreira R, Pinto M, Borges V, Duarte S, Vieira L, Gomes JP.
505 2023. Molecular Capture of *Mycobacterium tuberculosis* Genomes Directly from
506 Clinical Samples: A Potential Backup Approach for Epidemiological and Drug
507 Susceptibility Inferences. *IJMS* 24:2912.
- 508 22. Kok NA, Peker N, Schuele L, de Beer JL, Rossen JWA, Sinha B, Couto N. 2022. Host
509 DNA depletion can increase the sensitivity of *Mycobacterium* spp. detection through
510 shotgun metagenomics in sputum. *Front Microbiol* 13:949328.
- 511 23. Mann BC, Jacobson KR, Ghebrekristos Y, Warren RM, Farhat MR. 2023. Assessment
512 and validation of enrichment and target capture approaches to improve *Mycobacterium*
513 *tuberculosis* WGS from direct patient samples. bioRxiv
514 <https://doi.org/10.1101/2023.03.12.530724>.
- 515 24. Epperson LE, Strong M. 2020. A scalable, efficient, and safe method to prepare high
516 quality DNA from mycobacteria and other challenging cells. *Journal of Clinical*
517 *Tuberculosis and Other Mycobacterial Diseases* 19:100150.
- 518 25. Shehadul Islam M, Aryasomayajula A, Selvaganapathy PR. 2017. A Review on
519 Macroscale and Microscale Cell Lysis Methods. *Micromachines (Basel)* 8:83.
- 520 26. Zhou J, Zhang M, Li X, Wang Z, Pan D, Shi Y. 2021. Performance comparison of four
521 types of target enrichment baits for exome DNA sequencing. *Hereditas* 158:10.
- 522 27. Datta S, Shah L, Gilman RH, Evans CA. 2017. Comparison of sputum collection
523 methods for tuberculosis diagnosis: a systematic review and pairwise and network
524 meta-analysis. *The Lancet Global Health* 5:e760–e771.

- 525 28. Meyer AJ, Atuheire C, Worodria W, Kizito S, Katamba A, Sanyu I, Andama A, Ayakaka
526 I, Cattamanchi A, Bwanga F, Huang L, Davis JL. 2017. Sputum quality and diagnostic
527 performance of GeneXpert MTB/RIF among smear-negative adults with presumed
528 tuberculosis in Uganda. PLOS ONE 12:e0180572.

529

530

531

532

533

534

535

536